专访北大肿瘤医院院长:中国抗癌之路怎么走

2016-09-27 李雯 新华社

近日,一种被误读为“用小苏打‘饿死’癌细胞”的抗癌疗法引发热议。虽是讹传,但表明“抗癌”话题公众关注度颇高。多种因素作用下,全球癌症发病率不断攀升,抗癌成为医学界热点研究方向,中国也不例外。 今年年初美国政府提出的抗癌“登月计划”近日有了新的进展,由美国癌症专家组成的“蓝丝带顾问咨询委员会”建议,应在免疫疗法、数据共享和建立患者网络等十大领域重点投资,从而达到加快癌症研究的目的。

近日,一种被误读为“用小苏打‘饿死’癌细胞”的抗癌疗法引发热议。虽是讹传,但表明“抗癌”话题公众关注度颇高。多种因素作用下,全球癌症发病率不断攀升,抗癌成为医学界热点研究方向,中国也不例外。

今年年初美国政府提出的抗癌“登月计划”近日有了新的进展,由美国癌症专家组成的“蓝丝带顾问咨询委员会”建议,应在免疫疗法、数据共享和建立患者网络等十大领域重点投资,从而达到加快癌症研究的目的。

北京大学肿瘤医院院长、北京市肿瘤防治研究所所长季加孚接受新华社记者专访时说,中国集中了各类癌症人群,有利于数据采集和进一步展开研究,如能打破顶尖研究机构和基层医院之间屏障,将使更多患者受益。

中国癌症特点

北京大学肿瘤医院提供的资料显示,中国癌症发病符合全球发病的规律,也有自己的特点。随着中国逐渐步入老龄化社会,癌症发病率也会不断提高,这是全球癌症发病的共性。此外,癌症与饮食习惯、吸烟、遗传因素和职业暴露等因素也有关系。

中国地域辽阔,经济发展不平衡,不同地区的癌症发病谱存在显著差异。

以消化道肿瘤为例。在沿海经济发达地区人们的饮食结构中,精细化、高脂肪、高热量的饮食更为常见,因此结直肠癌等下消化道肿瘤的发病率偏高;而经济欠发达地区的饮食相对粗糙,多食腌制食品,因此食管癌、胃癌等上消化道肿瘤更为多发。

中国城市地区的恶性肿瘤发病率高于农村地区,但死亡率低于农村地区。一方面因为城市地区诊疗水平更好;另一方面,由于癌谱不一样,预后相对较好的乳腺癌、结直肠癌、甲状腺癌在城市高发,预后相对较差的肝癌、食管癌和胃癌在农村常见。

随着城乡间社会经济水平、环境、生活方式差异逐渐缩小,城乡地区整体癌症发病率、死亡率以及癌谱构成也逐渐接近。

在中国,主要的恶性肿瘤包括肺癌、胃癌、肝癌、结直肠癌、食管癌、乳腺癌、甲状腺癌、宫颈癌、脑瘤和胰腺癌,约占全部发病的75%。2000年至2011年,中国男性癌症总发病率保持稳定,然而女性发病率有所上升,年均增长2.2%。

预防重于治疗

虽然全球医生、科学家努力几十年甚至上百年,但人类仍未完全攻克癌症。癌症一旦到了晚期,任何治疗手段都力不从心。预防癌症发生以及癌症早期发现被认为是治疗癌症的根本,正如中国政府不断提倡“抗癌要以预防为主、抗癌战略要前移”。

预防癌症,就要预防它的病因。当然,有些因素人们无法控制,比如种族、性别和不断增长的年龄等。但有些因素是人们可以主观控制的,如戒烟限酒、控制体重、合理膳食、坚持锻炼、保持心情愉快、避免病毒感染、远离辐射和有害化学物质等。

遗传因素在以前被认为是不可控制的因素。但随着科技的发展,基因测序已不像过去那么难。人们通过提早做基因检测,可以评估和管理癌症风险,使高危人群终生不患癌症或者在癌症早期防范。

美国女星安吉丽娜·朱莉为降低患癌风险切除双侧乳房后,遗传基因筛查、预防性器官切除在各国都掀起了不小的热度。中国乳腺癌遗传学家、北京大学肿瘤医院解云涛教授领导的团队经过10多年的积累,于2015年宣布发现了在中国遗传性乳腺癌人群中,可以与BRCA1、BRCA2基因相媲美的RECQL基因。

季加孚认为,在预防和治疗疾病之间,预防最重要,尽量不得病、少得病。易感人群应争取在癌症早期就得到控制。

更多患者受益

季加孚说,中国集中了各类癌症人群,有利于数据采集和进一步展开研究。如果能打破顶尖研究机构和基层医院之间的屏障,就会有更多的癌症患者受益。

实际上,北京大学肿瘤医院正在和国外的癌症中心及药物研发企业合作,获得每一个患者的基因数据,构建精准医疗数据库,按照不同临床试验所需目标患者的基因类型来匹配临床试验,目的就是为了使国内更多患者参加临床试验,最终让更多患者受益。

该院专家表示,想让更多患者参加临床试验,并且降低临床试验成本,实践中需要患者、医院、精准医疗数据库和药物研发公司紧密联系,建立良好的合作关系。

季加孚说,传染病能够很快传遍全球,但最先进的医疗技术并不能像传染病那样很快扩散。对中国而言,需要打破区域意识,加强沟通,进一步合作,使大城市的医疗机构研发出的技术和药物等能够尽快应用到基层患者的身上。

他认为,通过数据共享来加速全球抗癌研究已经成为国际共识。中国、美国、英国、荷兰等国都已经展开行动。中国首个国家基因库22日正式投入运营,美国6月已启用了抗癌“登月计划”首个大型开放数据库,美国、英国和荷兰的研究机构7月还合作建立了新的癌细胞培养模型库。 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703228, encodeId=fee51e032286b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 03 11:22:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723366, encodeId=fe8f1e233664a, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Wed Aug 09 08:22:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675657, encodeId=df3716e565734, content=<a href='/topic/show?id=868b35630f2' target=_blank style='color:#2F92EE;'>#医院院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35630, encryptionId=868b35630f2, topicName=医院院长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446427287674, createdName=xuyu, createdTime=Sun Feb 26 23:22:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136720, encodeId=f83c136e2003, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:14 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136719, encodeId=762c136e1946, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135870, encodeId=fda51358e052, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:10:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135869, encodeId=db08135869bf, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:49 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135868, encodeId=e32313586877, content=抗癌要以预防为主、抗癌战略要前移, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135867, encodeId=853413586e7a, content=预防重于治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:05 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1703228, encodeId=fee51e032286b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 03 11:22:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723366, encodeId=fe8f1e233664a, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Wed Aug 09 08:22:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675657, encodeId=df3716e565734, content=<a href='/topic/show?id=868b35630f2' target=_blank style='color:#2F92EE;'>#医院院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35630, encryptionId=868b35630f2, topicName=医院院长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446427287674, createdName=xuyu, createdTime=Sun Feb 26 23:22:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136720, encodeId=f83c136e2003, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:14 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136719, encodeId=762c136e1946, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135870, encodeId=fda51358e052, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:10:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135869, encodeId=db08135869bf, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:49 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135868, encodeId=e32313586877, content=抗癌要以预防为主、抗癌战略要前移, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135867, encodeId=853413586e7a, content=预防重于治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:05 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1703228, encodeId=fee51e032286b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 03 11:22:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723366, encodeId=fe8f1e233664a, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Wed Aug 09 08:22:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675657, encodeId=df3716e565734, content=<a href='/topic/show?id=868b35630f2' target=_blank style='color:#2F92EE;'>#医院院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35630, encryptionId=868b35630f2, topicName=医院院长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446427287674, createdName=xuyu, createdTime=Sun Feb 26 23:22:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136720, encodeId=f83c136e2003, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:14 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136719, encodeId=762c136e1946, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135870, encodeId=fda51358e052, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:10:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135869, encodeId=db08135869bf, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:49 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135868, encodeId=e32313586877, content=抗癌要以预防为主、抗癌战略要前移, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135867, encodeId=853413586e7a, content=预防重于治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:05 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
    2017-02-26 xuyu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1703228, encodeId=fee51e032286b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 03 11:22:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723366, encodeId=fe8f1e233664a, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Wed Aug 09 08:22:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675657, encodeId=df3716e565734, content=<a href='/topic/show?id=868b35630f2' target=_blank style='color:#2F92EE;'>#医院院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35630, encryptionId=868b35630f2, topicName=医院院长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446427287674, createdName=xuyu, createdTime=Sun Feb 26 23:22:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136720, encodeId=f83c136e2003, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:14 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136719, encodeId=762c136e1946, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135870, encodeId=fda51358e052, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:10:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135869, encodeId=db08135869bf, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:49 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135868, encodeId=e32313586877, content=抗癌要以预防为主、抗癌战略要前移, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135867, encodeId=853413586e7a, content=预防重于治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:05 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
    2016-09-27 知难而进

    继续关注!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1703228, encodeId=fee51e032286b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 03 11:22:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723366, encodeId=fe8f1e233664a, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Wed Aug 09 08:22:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675657, encodeId=df3716e565734, content=<a href='/topic/show?id=868b35630f2' target=_blank style='color:#2F92EE;'>#医院院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35630, encryptionId=868b35630f2, topicName=医院院长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446427287674, createdName=xuyu, createdTime=Sun Feb 26 23:22:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136720, encodeId=f83c136e2003, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:14 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136719, encodeId=762c136e1946, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135870, encodeId=fda51358e052, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:10:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135869, encodeId=db08135869bf, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:49 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135868, encodeId=e32313586877, content=抗癌要以预防为主、抗癌战略要前移, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135867, encodeId=853413586e7a, content=预防重于治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:05 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
    2016-09-27 知难而进

    谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1703228, encodeId=fee51e032286b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 03 11:22:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723366, encodeId=fe8f1e233664a, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Wed Aug 09 08:22:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675657, encodeId=df3716e565734, content=<a href='/topic/show?id=868b35630f2' target=_blank style='color:#2F92EE;'>#医院院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35630, encryptionId=868b35630f2, topicName=医院院长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446427287674, createdName=xuyu, createdTime=Sun Feb 26 23:22:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136720, encodeId=f83c136e2003, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:14 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136719, encodeId=762c136e1946, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135870, encodeId=fda51358e052, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:10:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135869, encodeId=db08135869bf, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:49 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135868, encodeId=e32313586877, content=抗癌要以预防为主、抗癌战略要前移, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135867, encodeId=853413586e7a, content=预防重于治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:05 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
    2016-09-27 医路开来

    谢谢分享,,

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1703228, encodeId=fee51e032286b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 03 11:22:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723366, encodeId=fe8f1e233664a, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Wed Aug 09 08:22:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675657, encodeId=df3716e565734, content=<a href='/topic/show?id=868b35630f2' target=_blank style='color:#2F92EE;'>#医院院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35630, encryptionId=868b35630f2, topicName=医院院长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446427287674, createdName=xuyu, createdTime=Sun Feb 26 23:22:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136720, encodeId=f83c136e2003, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:14 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136719, encodeId=762c136e1946, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135870, encodeId=fda51358e052, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:10:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135869, encodeId=db08135869bf, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:49 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135868, encodeId=e32313586877, content=抗癌要以预防为主、抗癌战略要前移, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135867, encodeId=853413586e7a, content=预防重于治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:05 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
    2016-09-27 医路开来

    学习啦,,,

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1703228, encodeId=fee51e032286b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 03 11:22:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723366, encodeId=fe8f1e233664a, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Wed Aug 09 08:22:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675657, encodeId=df3716e565734, content=<a href='/topic/show?id=868b35630f2' target=_blank style='color:#2F92EE;'>#医院院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35630, encryptionId=868b35630f2, topicName=医院院长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446427287674, createdName=xuyu, createdTime=Sun Feb 26 23:22:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136720, encodeId=f83c136e2003, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:14 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136719, encodeId=762c136e1946, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135870, encodeId=fda51358e052, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:10:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135869, encodeId=db08135869bf, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:49 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135868, encodeId=e32313586877, content=抗癌要以预防为主、抗癌战略要前移, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135867, encodeId=853413586e7a, content=预防重于治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:05 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
    2016-09-27 医路开来

    抗癌要以预防为主、抗癌战略要前移

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1703228, encodeId=fee51e032286b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat Jun 03 11:22:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723366, encodeId=fe8f1e233664a, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Wed Aug 09 08:22:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675657, encodeId=df3716e565734, content=<a href='/topic/show?id=868b35630f2' target=_blank style='color:#2F92EE;'>#医院院长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35630, encryptionId=868b35630f2, topicName=医院院长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446427287674, createdName=xuyu, createdTime=Sun Feb 26 23:22:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136720, encodeId=f83c136e2003, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:14 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136719, encodeId=762c136e1946, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 27 23:04:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135870, encodeId=fda51358e052, content=谢谢分享,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:10:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135869, encodeId=db08135869bf, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:49 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135868, encodeId=e32313586877, content=抗癌要以预防为主、抗癌战略要前移, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135867, encodeId=853413586e7a, content=预防重于治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Sep 27 13:09:05 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
    2016-09-27 医路开来

    预防重于治疗

    0

相关资讯

紧追辉瑞!FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格(BTD)

2016年8月5日讯,瑞士制药巨头诺华(Novartis)新型口服靶向抗癌药CDK4/6抑制剂LEE011(ribociclib)近日在美国监管方面传来喜讯。美国食品和药物管理局(FDA)已授予LEE011突破性药物资格(BTD),联合来该公司激素疗法Femara(品牌名:弗隆,通用名:letrozole,来曲唑)用于激素受体阳性/人类表皮生长因子受体2阴性(HR+/HER2-)晚期或转移性乳腺癌

Sci Rep:系统挖掘中草药抗癌潜力,发现300余种潜在化合物

中科院昆明动物所黄京飞课题组在从传统中草药中发掘抗癌植物和化合物研究中取得进展。相关成果日前在线发表于《科学报告》杂志。 我国传统中药数据库记录了2000多种药用植物。但在传统中草药中,只有小部分药用植物被充分系统地研究过。 针对这一现状,黄京飞课题组首先建立了一个抗肿瘤药物预测平台。基于该平台,他们开发了新的预测肿瘤靶标的方法,并成功预测了新的肺癌靶标。最近,科研人员又利用该平台和预

Nat Chemistry:新发现或将快速筛选抗癌化合物

图片来源:www.phys.org 近日,刊登于国际杂志Nature Chemistry上的一项研究报告中,来自芝加哥大学的一组研究人员设计了一种方法来制造目前很多化学家都无法合成出的小型多节且连锁的化学结构,研究者认为,这些特殊的化学结构能够被用来筛选可以抵御癌症的新型化合物。 很多化学家都将分节或链环作为其开发的化学结构的一部分,但在分子尺度下合成出繁杂的新型物质是非常困难的,而这项研

Cancer Res:新型抗癌策略可动员机体先天性和适应性的免疫反应

近日,刊登在国际杂志Cancer Research上的一项研究论文中,来自日本综合医学科学中心的研究人员通过研究开发了一种新型疫苗,该疫苗可以被注射到修饰过的细胞中来刺激产生先天性的免疫反应以及更为特殊的适应性反应,从而帮助机体维持记忆并且攻击新生的肿瘤细胞。尽管当前一系列基于免疫疗法的策略被用来抵御癌症,但这种疗法经常会无效的免疫应答而备受阻碍;本文中,研究者就设计出了了一种新型疫苗,该疫苗可以

“神药”米非司酮的18种用法,你用过几个?

米非司酮是妇产科常用的药物流产用药,有‘堕胎圣药’之称,所以国家管理的很严,没有专科医生的处方,一般人是搞不到的。不过,除了堕胎它还有很多其他的神奇用途,诸如抗癌、缩瘤、抗抑郁……还能治疗艾滋病……与前段时间炒的很火的‘神药’——阿司匹林、二甲双胍有过之而不及。受到匹林、双胍的‘刺激’之后,‘小米’再也无法寂静地沉默下去了!今天,笔者就带您走进‘小米’——米非司酮的内心世界!1.早期妊娠药物流

扒一扒“包治百病”的二甲双胍

导语:近些年,多项研究表明二甲双胍具有减重、延缓衰老、抗癌等作用。但是万物皆有两面性,即使是神药也不是十全十美的。二甲双胍自1957年问世以来,已经在国际上使用了近60年,在我国也已有近20年的使用经验。二甲双胍在各种2型糖尿病防治指南中,都处在一线用药的王牌地位。但二甲双胍的“野心”还不止于此——近年来,大量研究发现,二甲双胍还有抗衰老、抗癌等“特异功能”。今天我们就先来“肢解”二甲双胍的“